{"id":31602,"date":"2025-09-04T14:09:13","date_gmt":"2025-09-04T14:09:13","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/halia-therapeutics-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference\/"},"modified":"2025-09-04T14:09:13","modified_gmt":"2025-09-04T14:09:13","slug":"halia-therapeutics-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=31602","title":{"rendered":"Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

LEHI, Utah<\/span><\/span>, Sept. 4, 2025<\/span><\/span> \/PRNewswire\/ — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced that the Company plans to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference.<\/p>\n

Jared Bearss<\/span>, Chief Operating Officer of Halia, will provide a business overview presentation on Tuesday, September 9, 2025<\/span> at 7:00 am ET<\/span>.<\/p>\n

About Halia Therapeutics<\/b><\/p>\n

Halia Therapeutics is a clinical-stage biopharmaceutical company focused on treating the root causes of inflammation. Leveraging genetic insights and AI-enabled discovery, Halia is building a robust pipeline of novel therapeutics based on genetic resilience that targets inflammatory pathways in diseases ranging from metabolic disorders to neurodegeneration and hematologic malignancies.<\/p>\n

Halia’s mission is to create data-driven therapies that not only extend life but also improve its quality. The company is headquartered in Lehi, Utah<\/span>, and is actively advancing global partnerships in clinical research, drug discovery, and personalized medicine.<\/p>\n

To learn more, visit www.haliatx.com<\/a> or follow us on LinkedIn and Twitter @HaliaTx.<\/p>\n

Media Contact<\/b><\/p>\n

Taylor Avei\u00a0
Director of Business Development
Halia Therapeutics
info@haliatx.com<\/a><\/p>\n

Investor Contact<\/b><\/p>\n

Leigh Salvo\u00a0
New Street Investor Relations
leigh@newstreetir.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

LEHI, Utah<\/span><\/span>, Sept. 4, 2025<\/span><\/span> \/PRNewswire\/ — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced that the Company plans to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference.<\/p>\n

Jared Bearss<\/span>, Chief Operating Officer of Halia, will provide a business overview presentation on Tuesday, September 9, 2025<\/span> at 7:00 am ET<\/span>.<\/p>\n

About Halia Therapeutics<\/b><\/p>\n

Halia Therapeutics is a clinical-stage biopharmaceutical company focused on treating the root causes of inflammation. Leveraging genetic insights and AI-enabled discovery, Halia is building a robust pipeline of novel therapeutics based on genetic resilience that targets inflammatory pathways in diseases ranging from metabolic disorders to neurodegeneration and hematologic malignancies.<\/p>\n

Halia’s mission is to create data-driven therapies that not only extend life but also improve its quality. The company is headquartered in Lehi, Utah<\/span>, and is actively advancing global partnerships in clinical research, drug discovery, and personalized medicine.<\/p>\n

To learn more, visit www.haliatx.com<\/a> or follow us on LinkedIn and Twitter @HaliaTx.<\/p>\n

Media Contact<\/b><\/p>\n

Taylor Avei\u00a0
Director of Business Development
Halia Therapeutics
info@haliatx.com<\/a><\/p>\n

Investor Contact<\/b><\/p>\n

Leigh Salvo\u00a0
New Street Investor Relations
leigh@newstreetir.com<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-31602","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31602"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31602\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}